secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch Health Companies Inc. (BHC)
CIK:        0000885590
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001193125-25-167131
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch Health to acquire DURECT for $1.75/share ($63M upfront) plus up to $350M milestones
--------------------------------------------------------------------------------

- Bausch Health will pay $1.75/share cash upfront, valuing DURECT at ~$63M, with up to $350M in additional net sales milestone payments.
- The upfront price represents a ~191% premium to DURECT's 30-day VWAP and ~217% premium to the July 28 closing price.
- DURECT's lead asset larsucosterol has FDA Breakthrough Therapy Designation for alcoholic hepatitis, with planned Phase 3 trial.
- Transaction expected to close in Q3 2025, subject to majority tender and customary conditions.
- Acquisition complements Bausch's hepatology pipeline alongside ongoing rifaximin SSD Phase 3 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885590/000119312525167131/0001193125-25-167131-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885590/000119312525167131/d943437d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-167131

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer